Traws Pharma IncTRAW
▲ PositiveCapitalrelevance
Q2 adjusted loss beat expectations, though revenue was nil and cash runway extends into Q1 2027.
Impact on stocks 1
Biotech & Genomic Medicine
Traws Pharma IncTraws Pharma shares gained 3.9% in pre-market trading after the clinical-stage biopharmaceutical company reported a second-quarter adjusted loss of $0.16 per share, beating the analyst consensus estimate for a loss of $0.43 per share. The company generated no revenue during the quarter, compared with $2.7 million in the corresponding period of 2025, a decline driven by non-recurring deferred revenue from a terminated licensing agreement. Traws Pharma is targeting a third-quarter resubmission of tivoxavir marboxil to UK regulators and aims to resolve a US FDA clinical hold by the end of 2026. Research and development spending fell to $1.1 million from $2.3 million a year earlier, while general and administrative expenses rose to $3.5 million from $1.7 million. The company ended the quarter with $5.0 million in cash and expects its resources to fund operations into the first quarter of 2027.
Traws Pharma IncQ2 adjusted loss beat expectations, though revenue was nil and cash runway extends into Q1 2027.